Emerging proteomics biomarkers and prostate cancer burden in Africa

Henry A. Adeola; Jonathan M. Blackburn; Timothy R. Rebbeck; Luiz F. Zerbini

doi:10.18632/oncotarget.16568

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Emerging proteomics biomarkers and prostate cancer burden in Africa

Henry A. Adeola, Jonathan M. Blackburn, Timothy R. Rebbeck and Luiz F. Zerbini _

PDF | HTML | How to cite

Oncotarget. 2017; 8:37991-38007. https://doi.org/10.18632/oncotarget.16568

Metrics: PDF 2712 views | HTML 5333 views | ?

Abstract

Henry A. Adeola1,2, Jonathan M. Blackburn2,3,Timothy R. Rebbeck4 and Luiz F. Zerbini1,2

1 International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa

2 Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

3 Institute of Infectious Disease & Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

4 Harvard T.H. Chan School of Public Health and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Correspondence to:

Luiz F. Zerbini, email:

Keywords: proteomics, biomarker, prostate cancer, Africa, mass spectrometer

Received: November 23, 2016 Accepted: February 27, 2017 Published: March 25, 2017

Abstract

Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16568

Publication Alerts

Reviews:

Emerging proteomics biomarkers and prostate cancer burden in Africa

Abstract